Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes
Christine P. Limonte(University of Washington Medical Center), Viktor R. Drel(Pennington Biomedical Research Center), Trevor J. Orchard(University of Pittsburgh), Robert D. Toto(Southwestern Medical Center), Viji Nair(University of Michigan), Tarunveer S. Ahluwalia(Steno Diabetes Centers), Carol Forsblom(University of Helsinki), Per‐Henrik Groop(University of Helsinki), Andrew N. Hoofnagle(University of Washington), Ian H. de Boer(The Ohio State University), Erkka Valo(University of Helsinki), Loki Natarajan(General Department of Preventive Medicine), Insa M. Schmidt(Boston University), Tina Costacou(University of Pittsburgh), Niina Sandholm(University of Helsinki), Janet K. Snell‐Bergeon(University of Colorado Anschutz Medical Campus), Daniel Montemayor(The University of Texas at San Antonio Health Science Center), Sushrut S. Waikar(Metabolism and Renal Physiology), Matthias Kretzler(University of Michigan), Wenjun Ju(Xuzhou Medical College), Clark M. Henderson(University of Washington), Subramaniam Pennathur(University of Michigan), Tomáš Vaisar, Peter Rossing(Steno Diabetes Centers), Sylvia E. Rosas(Joslin Diabetes Center), Robert G. Nelson(Joslin Diabetes Center), Kumar Sharma(The University of Texas at San Antonio Health Science Center), Jing Zhang(Hunan University), John F. O’Toole(Cleveland Clinic), Manjula Darshi(Howard Hughes Medical Institute), John Ruzinski(University of Washington)
Cited by 37
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k